111 related articles for article (PubMed ID: 21905526)
1. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
Cotter D; Thamer M; Zhang Y
Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
[No Abstract] [Full Text] [Related]
2. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
3. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
4. Implications of Medicare Part D in CKD anemia treatment.
Stefanacci RG
J Am Med Dir Assoc; 2006 Nov; 7(9 Suppl):S13-6; quiz S17-21. PubMed ID: 17098632
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin, an update, and where to in the future?
Sulková S
EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
[TBL] [Abstract][Full Text] [Related]
6. Medicare program; coverage of epoetin (EPO) used by competent home dialysis patients--HCFA. Final rule.
Fed Regist; 1994 Jan; 59(6):1278-85. PubMed ID: 10133081
[TBL] [Abstract][Full Text] [Related]
7. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
8. Medicare and erythropoietin.
Steinbrook R
N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
[No Abstract] [Full Text] [Related]
9. The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia.
Eggers PW; Greer J; Jencks S
Am J Kidney Dis; 1994 Aug; 24(2):247-54. PubMed ID: 8048432
[TBL] [Abstract][Full Text] [Related]
10. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
11. Long-term home health care: what are the costs of care and costs of failure to give care?
Rodat C
J Long Term Home Health Care; 1996; 15(1):30-46. PubMed ID: 10156794
[No Abstract] [Full Text] [Related]
12. The intended-and unintended-consequences of healthcare reform.
Hammer D; Phillips B; Schmidt TL
Healthc Financ Manage; 2010 Oct; 64(10):50-5. PubMed ID: 20922899
[TBL] [Abstract][Full Text] [Related]
13. Catch a falling star: wonder drug EPO may be down, but not out.
Neumann ME
Nephrol News Issues; 2010 Sep; 24(10):8. PubMed ID: 20942325
[No Abstract] [Full Text] [Related]
14. Selected research topics.
Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):96-104. PubMed ID: 1951363
[No Abstract] [Full Text] [Related]
15. The ESRD demonstration project: what it accomplished. Fresenius Medical Care North America.
Sauer PF; Farrell RE; Lazarus JM
Nephrol News Issues; 2011 Jun; 25(7):32, 34-5, 37-8. PubMed ID: 21736133
[No Abstract] [Full Text] [Related]
16. Report from the University Healthsystem Consortium.
Int J Technol Assess Health Care; 1999; 15(2):437-8. PubMed ID: 10507201
[No Abstract] [Full Text] [Related]
17. Investing in health care reform.
Davis K
N Engl J Med; 2009 Feb; 360(9):852-5. PubMed ID: 19228700
[No Abstract] [Full Text] [Related]
18. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
19. External monitoring of quality of health care in the United States.
Wareham NJ
Qual Health Care; 1994 Jun; 3(2):97-101. PubMed ID: 10137592
[No Abstract] [Full Text] [Related]
20. Health care coverage and drug costs--the candidates speak out.
Bush GW; Kerry JF
N Engl J Med; 2004 Oct; 351(18):1815-9. PubMed ID: 15509811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
